• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Essilor acquires J&J ophthalmic lens business

Article

Dallas—Essilor will acquire Johnson & Johnson Vision Care Inc.'s Spectacle Lens Group, including the group's Definity brand of progressive lenses.

Dallas-Essilor will acquire Johnson & Johnson Vision Care Inc.'s Spectacle Lens Group, including the group's Definity brand of progressive lenses.

The group is Johnson & Johnson Vision Care Inc.'s ophthalmic lens business. Terms of the deal, announced June 8, were not disclosed.

The Definity progressive lenses, introduced to U.S. test markets in late 2002, feature "Dual Add" technology that divides progressive add power between the front and back surfaces. Essilor will continue to manufacture the lenses and distribute them through its marketing and distribution networks.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
© 2024 MJH Life Sciences

All rights reserved.